

DATA ON FILE: Document E

Studies have been conducted in the following countries:

Australia, Austria, Canada France, Germany, Greece, India, Italy, Japan, Lebanon, Norway, Sweden
[We have published studies from Denmark, Netherlands, UK, US, Switzerland]

FRANCE: Spaeth, D., Luporsi, E, Weber, S, et al (2008). "Efficacy and safety of cooling helmets for the prevention of chemotherapy-induced alopecia: A prospective study of 911 patients." J Clin Oncol 26 (May Suppl)(abstract 9564).

GREECE: Christodoulou, C. T., G, Galani, E, Skarlos, DV (2006). "Scalp metastases and scalp cooling for chemotherapy-induced alopecia prevention." Ann Oncol 17(2): 350.

NETHERLANDS: C. van den Hurk, e. a. (2011). Multicenter results of scalp cooling to prevent chemotherapy-induced alopecia in 1500 breast cancer patients. . San Antonio Breast

SWITZERLAND: Betticher DC, Delmore G, Breitenstein U, Anchisi S, Zimmerli-Schwab B, Müller A, et al. Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment. Support Care Cancer. 2013;21:2565-2573. doi:10.1007/s00520-013-1804-9.

NETHERLANDS: Komen MMC, Smorenburg CH2, Nortier JW, Ploeg T, van den Hurk CJ, Hoeven JJ. Results of scalp cooling during anthracycline containing chemotherapy depend on scalp skin temperature. Breast. 2016;30:105-110. doi:10.1016/j.breast.2016.09.007


NETHERLANDS: Komen MMC, Breed WP, Smorenburg CH, Ploeg T, Goey SH, Hoeven JJ, Nortier JW, van den Hurk CJ. Results of 20- versus 45-min post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Support Care Cancer. 2016;24:2735-2741. doi:10.1007/s00520-016-3084-7.

UK: Massey, C. (2004). "A multicentre study to determine the efficacy and patient acceptability of the Paxman Scalp Cooler to prevent hair loss in patients receiving chemotherapy." European Journal of Onc Nursing 8: 121-130.

NETHERLANDS: van den Hurk CJ, Breed WP, Nortier JW. Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Support Care Cancer. 2012;20:3255-3260. doi:10.1007/s00520-012-1465-0.

NETHERLANDS: van den Hurk CJ, Winstanley J, Young A, Boyle F. Measurement of chemotherapy-induced alopecia-time to change. Support Care Cancer. 2015;23:1197-1199. doi:10.1007/s00520-015-2647-3.

NETHERLANDS: Peerbooms M, van den Hurk CJG, Breed WPM Familiarity, opinions, experiences and knowledge about scalp cooling: a Dutch survey among breast cancer patients and oncological professionals 10.4103/2347-5625.152404 Asia Pacific Journal of Oncology Nursing Jan-Mar 2014



Posters

DENMARK: Anne Margrethe Jørgensen, RSN, Herning Hospital, Denmark. SCALP COOLING IN CONJUNCTION WITH CHEMOTHERAPY Consecutive results during a two year period using the Paxman Hair Loss Prevention System Aug 2001 - 2003

GERMANY: Kurbacher C, Herz, Kolberg, Kettelhoit, Kurbacher J, Schweitzer SENSOR-CONTROLLED SCALP COOLING IN THE CLINICAL ROUTINE: AN EFFECTIVE AND SAFE METHOD TO PREVENT CHEMOTHERAPY-INDUCED ALOPECIA IN WOMEN WITH BREAST OR FEMALE GENITAL TRACT CANCER. Presented at ECC Amsterdam 2017

NORWAY: De Vries NF and Andersen OK Scalp cooling as a method of avoiding alopecia in cancer patients receiving chemotherapy. Presented at ECCO Lisbon 2011

USA: Nangia J, Wang T, Osborne C, Nirvath P, Otte K, Papish S et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer. The SCALP randomized clinical trial. JAMA. 2017;317:596-605. Doi:10.1001/jama.2016.20939

NETHERLANDS: van den Hurk Cl, et al. Scalp Cooling to prevent alopecia after chemotherapy can be considered safe in patients with breast cancer. Breast 2013;22(5): 1001-1004

NETHERLANDS: van den Hurk C, Komen M, Hussain O, Al-Tameemi W, Paus R, Collett A, Haslam I, et al (Pre) clinical research to understand alopecia and improve scalp cooling results 2015

LEBANON: Professor Fadi Nasr, personal communication (Lebanon)

Ongoing trials:

Japan

India – TATA Memorial Hospital

Germany – Luisenkrankenhaus, Düsseldorf, Germany